Drug intelligence / Profile preview

HUCi-622

Development stage: Preclinical
Lead developer: Huons
Modality: Small Molecules

Overview

HUCi-622 is a small molecule drug candidate currently in preclinical development by Huons for the treatment of obesity. Classified as a New Chemical Entity (NCE), it is part of Huons's metabolic pipeline aimed at addressing weight management. As of early 2026, the specific molecular target and mechanism of action for HUCi-622 remain undisclosed by the developer. The compound is being evaluated alongside other obesity-focused candidates in the Huons portfolio, such as HUCi-670 and the GLP-1 receptor agonist HUC2-676.

Beyond the preview

Go deeper on HUCi-622.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUCi-622.

Explore the full profile